Regeneron announced manufacturing and supply agreement for BARDA and U.S. DoD for REGN-COV2 anti-viral antibody cocktail
On Jul. 7, 2020, Regeneron announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and…
-
-
Corvus Pharmaceuticals initiated clinical trial of novel immunotherapy for patients with COVID-19
On Jul. 7, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
-
Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics
On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in…
-
Anixa Biosciences and OntoChem announced completion of initial screening program and identification of additional Covid-19 compounds
On Jul. 6, 2020, Anixa Biosciences announced that it and partner OntoChem had completed the initial in silico…
-
WHO discontinued hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
On Jul. 4, 2020, the World Health Organization (WHO) accepted the recommendation from the Solidarity Trial’s International Steering…
-
CytoDyn announced exclusive agreement for distribution and supply of leronlimab for treatment of COVID-19 in U.S.
On Jul. 3, 2020, CytoDyn announced it had signed an exclusive Distribution and Supply Agreement with American Regent…
-
Biotechnology | FDA | HIV | Therapeutics
The FDA approved new HIV treatment for patients with limited treatment options
On Jul. 2, 2020, the U.S. Food and Drug Administration (FDA) approved Rukobia (fostemsavir), a new type of…
-
UConn-made COVID-19 custom mask solution to be manufactured
On Jul. 2, 2020, UConn announced a licensing deal with Connecticut Biotech, a startup company headquartered in South…
-
Regeneron and Sanofi announced Kevzara (sarilumab) phase 3 US trial in COVID-19 patients did not meet endpoints
On Jul. 2, 2020, Regeneron and Sanofi announced that the U.S. Phase 3 trial of Kevzara (sarilumab) 400…
-
Intravacc in-licensed CimCure’s iBoost technology, expanding its vaccine platform portfolio
On Jul. 1, 2020, Intravacc announced the signing of a strategic partnership agreement with Dutch based CimCure, focusing…
-
Fujifilm partnered with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan
On Jul. 1, 2020, FUJIFILM announced a partnership with Dr. Reddy’s Laboratories, a global pharmaceutical company headquartered in…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Non-Profit Research | Therapeutics | Vaccine
MSFHR funded COVID-19 research to mitigate effects on BC’s vulnerable populations
On Jun. 29, 2020, the Michael Smith Foundation for Health Research (MSFHR) COVID-19 Research Response Fund announced funding…
-
COVID-19 Therapeutics Accelerator donors launched international alliance to connect research data sources and enable collaboration
On Jun. 26, 2020, the COVID-19 Therapeutics Accelerator donors and partners announced the formation of the International COVID-19…
-
University of Alberta researcher to test whether COVID-19 antibodies provide long-term immunity
On Jun. 25, 2020, the University of Alberta (U of A) announced a study that will analyze thousands…
-
The FDA approved new therapy for Dravet Syndrome
On Jun. 25, 2020, the U.S. Food and Drug Administration (FDA) approved Fintepla (fenfluramine), a Schedule IV controlled…
-
Government of Canada and provincial partners invested more than $109 mllion in COVID-19 research
On Jun. 25, 2020, the Government of Canada announced the results of that funding competition: an investment of…
-
University of British Columbia received $14 million in federal funding for COVID-19 research
On Jun. 25, 2020, researchers at the University of British Columbia announced they had received a combined total…
-
SIGA Technologies announced deliveries of oral TPOXX to HHS valued at approximately $32 million
On Jun. 25, 2020, SIGA Technologies announced the deliveries of oral TPOXX (tecovirimat) to the U.S. Department of…
-
Biotechnology | Diagnostics | Disease | Neurology | NIH | Therapeutics
Seattle researchers teamed up to build hi-res brain map of Alzheimer’s disease
On Jun. 25, 2020, the Allen Institute announced a new a new $40.5 million collaborative research center in…
-
Mateon selected by IBM Watson Health for use of IBM Clinical Development Solution to support clinical COVID-19 vaccine candidates
On Jun. 24, 2020, Oncotelic, a wholly owned subsidiary of Mateon Therapeutics, announced that IBM has granted access…
-
RedHill Biopharma announced data from severe COVID-19 patients showed substantial benefit to patients
On Jun. 24, 2020, RedHill Biopharma announced that results from the treatment of the first severe COVID-19 patients…
-
Mateon selected IQVIA for its randomized, controlled, multi-menter clinical study to test OT-101 as treatment for COVID-19 patients
On Jun. 23, 2020, Mateon Therapeutics announced it had selected IQVIA to manage C001, a Phase 2 randomized,…
-
Catalent partnered with ViralClear Pharmaceuticals on potential treatment for COVID-19
On Jun. 22, 2020, Catalent announced that it had signed an agreement with ViralClear Pharmaceuticals, a subsidiary of…
-
Taconic Biosciences announced distribution of critical COVID-19 mouse model
On Jun. 22, 2020, Taconic Biosciences announced an exclusive agreement with the University of Texas Medical Branch at…
-
The NIH halted clinical trial of hydroxychloroquine
On Jun. 20, 2020, the National Institutes of Health (NIH) announced that a clinical trial to evaluate the…
-
The FDA approved first therapy for rare disease that causes low phosphate blood levels, bone softening
On Jun. 18, 2020, the U.S. Food and Drug Administration (FDA) approved Ultragenyx Pharmaceutical ‘s Crysvita (burosumab-twza) injection…
-
Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaboration
On Jun. 18, 2020, Tonix Pharmaceuticals announced an expansion of its strategic collaboration with Southern Research to include…
-
ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…
-
Biotechnology | COVID-19 | Therapeutics | WHO
WHO announced preliminary results about dexamethasone use in treating critically ill COVID-19 patients
On Jun. 16, 2020, the World Health Organization (WHO) announced that initial clinical trial results from the United…
-
San Diego’s scientific and medical institutes collaborated on large-scale research program to study spread of COVID-19
On Jun. 16, 2020, a consortium that includes many of San Diego’s top medical and scientific research institutes…
